Discovery of YKS-34 , a Highly Selective PDE4B Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) remains a progressive and fatal lung disease with a substantial unmet need for safe and effective therapies. Highly selective inhibition of phosphodiesterase 4B (PDE4B) represents a promising therapeutic strategy for IPF while avoiding nausea and vomiting associated with PDE4D inhi...